As other retrospective studies and xenograft models have shown that HER2-targeted monoclonal antibody therapies might even be able to target HER2-nonamplified cancer cells and cancer stem cell populations including CTCs, the indication for HER2-targeted therapies might need to be extended [25, 26]. The gene discussed is ERBB2; the disease is cancer.